Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

Abstract Background The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an...

Full description

Bibliographic Details
Main Authors: Miguel Quintela-Fandino, Juan V. Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer, Juan Guerra
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Breast Cancer Research
Subjects:
Phase 0 clinical trial
Phase I clinical trial
Pharmacodynamics
FGFR1
FGF23
Letrozole
Online Access:http://link.springer.com/article/10.1186/s13058-019-1152-x

Internet

http://link.springer.com/article/10.1186/s13058-019-1152-x

Similar Items